Photo from Philip Kantoff/LinkedIn
Dec 29, 2023, 16:53
Philip Kantoff: RayzeBio brought a new therapy to the clinic to benefit patients with neuroendocrine tumors
Philip Kantoff, Co-Founder and Chief Executive Officer at Convergent Therapeutics, shared on LinkedIn:
“Congratulations to my son Aaron Kantoff, who co-founded RayzeBio, which brought a new therapy to the clinic to benefit patients with neuroendocrine tumors and after a little over 3 years RayzeBio was sold to BMS for 4.1b.”
Source: Philip Kantoff/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18